26
Nov
The Centers for Medicare & Medicaid Services (CMS) has just announced the prices that the federal government negotiated for 15 high-cost drugs covered by Part D, Medicare’s prescription drug benefit program, including the popular diabetes and obesity drugs Ozempic and Wegovy. This brings to a close the second round of Medicare’s Drug Price Negotiation Program, which was created by the Inflation Reduction Act of 2022 under the Biden administration. These negotiated prices will take effect in Medicare in January 2027.
